Bristol Myers Squibb announces that on December 6, its Board of Directors authorized the repurchase of an additional $3 billion of common stock under the multi-year share repurchase program.

With this increase, the pharmaceutical group's total share repurchase authorization is approximately $5 billion. The program allows management to make repurchases at its discretion.

The timing and amount of any share repurchases under the authorization will be determined at a later date by management, at its discretion and based on market conditions and other considerations.

Copyright (c) 2023 All rights reserved.